CorMedix Q4 2024 net revenue $31.2M, first profitable quarter; H1 2025 guidance $50-60M

CorMedix Inc.

Q4 2024 net revenue $31.2M; net income $13.5M ($0.22/diluted share); adjusted EBITDA $15.3M.
Full year 2024 net revenue $43.5M; net loss narrowed to $17.9M ($0.30/share) from $46.3M in 2023.
Preliminary H1 2025 revenue guidance $50-60M (Q1 >$33M); cash operating expense guidance $72-78M reaffirmed.
Cash and short-term investments $51.7M at Dec 31, 2024; expects >$75M at Q1 2025 end.
Inpatient sales team with Syneos Health nearly complete; Phase 3 DefenCath TPN study to start Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.